Scientists are actively working on a hantavirus vaccine, but its widespread availability is likely years away due to significant funding challenges and the sporadic nature of outbreaks. A recent hantavirus outbreak on the MV Hondius cruise ship has renewed focus on these development efforts. UK-based EnsiliTech is developing an mRNA-based vaccine, which has shown promise in rodent trials but has not yet entered human testing.